Medical device developer, REVA Medical Incorporated
(ASX:RVA) has announced it has been granted approval to expand its coronary scaffold product trial into more complex cases in Germany.
The product, FANTOM II is designed to restore blood flow to patients who are being treated for coronary artery disease (CAD). The scaffold is then absorbed by the body over time.
The recent approval allows REVA to expand its clinical trial to patients who have up to two lesions in one or more coronary arteries, with lesions longer than 20 mm.
REVA Medical says it saw excellent results from its first trial with 240 patients, while its more complex clinical trial is also expected to be advantageous.
